As of 2026-10-15, the Relative Valuation of Neuropace Inc (NPCE) is (17.30) USD. This relative valuation is based on P/E multiples. With the latest stock price at 12.68 USD, the upside of Neuropace Inc based on Relative Valuation is -236.4%.
The range of the Relative Valuation is (18.37) - (17.57) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 32.8x - 37.2x | 34.4x |
| Forward P/E multiples | 24.3x - 31.3x | 27.3x |
| Fair Price | (18.37) - (17.57) | (17.30) |
| Upside | -244.9% - -238.6% | -236.4% |
| Date | P/E |
| 2026-10-09 | -22.60 |
| 2026-10-08 | -22.10 |
| 2026-10-07 | -22.76 |
| 2026-10-06 | -22.60 |
| 2026-10-05 | -23.58 |
| 2026-10-02 | -22.65 |
| 2026-10-01 | -23.45 |
| 2026-09-30 | -24.54 |
| 2026-09-29 | -24.86 |
| 2026-09-28 | -25.24 |
| 2026-09-25 | -25.08 |
| 2026-09-24 | -24.92 |
| 2026-09-23 | -25.34 |
| 2026-09-22 | -26.24 |
| 2026-09-21 | -25.93 |
| 2026-09-18 | -25.47 |
| 2026-09-17 | -25.24 |
| 2026-09-16 | -25.15 |
| 2026-09-15 | -25.42 |
| 2026-09-14 | -26.02 |
| 2026-09-11 | -25.04 |
| 2026-09-10 | -24.74 |
| 2026-09-09 | -25.86 |
| 2026-09-08 | -26.32 |
| 2026-09-04 | -26.57 |
| 2026-09-03 | -26.31 |
| 2026-09-02 | -27.09 |
| 2026-09-01 | -26.29 |
| 2026-08-31 | -26.13 |
| 2026-08-28 | -25.70 |
| 2026-08-27 | -25.20 |
| 2026-08-26 | -26.18 |
| 2026-08-25 | -25.25 |
| 2026-08-24 | -24.95 |
| 2026-08-21 | -25.02 |
| 2026-08-20 | -25.00 |
| 2026-08-19 | -26.11 |
| 2026-08-18 | -25.81 |
| 2026-08-17 | -25.47 |
| 2026-08-14 | -26.34 |
| 2026-08-13 | -25.88 |
| 2026-08-12 | -25.97 |
| 2026-08-11 | -26.84 |
| 2026-08-10 | -26.54 |
| 2026-08-07 | -26.45 |
| 2026-08-06 | -24.79 |
| 2026-08-05 | -24.43 |
| 2026-08-04 | -25.22 |
| 2026-08-03 | -24.08 |
| 2026-07-31 | -22.99 |